Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Enzyme complex thought to promote cancer development can also help prevent it

14.10.2005


In a case of basic science detective work, researchers at The University of Texas M. D. Anderson Cancer Center have solved the puzzle of the "inconsistent biomarker" and, in the process, may have discovered an agent that can suppress cancer development.



In the Oct. 14 issue of Science, researchers report that the biomarker in question - an enzyme known as EZH2 - leads a duplicitous life. In its "native" state, the enzyme acts as a suppressor for cancer cell growth that works to inhibit cancer development. But when it is phosphorylated (when a phosphate group is added to the molecule), it turns vicious and acts to promote oncogenesis.

The researchers found the two forms of EZH2 after they identified the "switch" that leads to its phosphorylation - the well-known culprit Akt, an enzyme that has already been associated with cancer development.


The findings explain not only why high levels of EZH2 (when bound to its partner proteins, such as EED) have been shown to identify people who have an aggressive, metastatic form of breast or prostate cancer, but also why elevated levels of EED appear to offer protective effects against virulent lymphoma.

"This has become a big riddle to cancer researchers who want to be able to use EZH2 as a marker upon which to base aggressive treatment," says the study’s lead author, Mien-Chie Hung, Ph.D., chair of the Department of Molecular and Cellular Oncology. "We now know there are two different forms of EZH2. The phosphorylated one enhances oncogenesis, whereas the nonphosphorylated EZH2 works to inhibit cell growth."

Their findings are important for a number of different reasons, says Hung.

The first is that phosphorylated EZH2 may provide a much better "biomarker" of aggressive cancer than "total" EZH2 (the sum of both kinds of EZH2 that has been measured in previous biomarker studies) since it is the one with oncogenic properties and appears to help cancer cells invade nearby tissue, he says. "We need more study to determine this, but my prediction is that this form may be a better marker because it enhances the growth of cancer cells and tumors," he says.

The second is that the researchers developed a "mutant" protein that stops EZH2 from being phosphorylated, and they say this molecule might provide the basis for either a small-molecule drug or a gene therapy treatment, Hung says. Indeed, in their study, the research team used the agent to reduce tumor growth in a mouse model of human breast cancer. "We believe that identifying small molecules that could switch between the phosphorylated and nonphosphorylated EZH2 form may provide a screening strategy for cancer treatment," he says.

Finally, the study demonstrates the power of researching what is known as "epigenetics" molecular mechanisms in cancer - the notion that genes and their protein products do not have to be mutated for the disease to develop. In this field of study, researchers look at how beneficial genes/proteins may be silenced by molecules that help handle DNA.

For example, one area of active investigation is the power that histones exert on gene expression. Histones are nature’s way of physically controlling unwieldy "naked" DNA by compacting it. But scientists now know that histones themselves can be modified by phosphorylation, as well as through another process known as methylation, in which one atom on a biological molecule is replaced by a different set of chemicals. Histone methylation, in particular, is now regarded as a strong modifier of genetic activity, and can work to either activate or silence gene expression.

The M. D. Anderson researchers conclude that Akt regulates the ability of EZH2 to silence genes that are needed to protect against cancer development. When Akt is activated, it phosphorylates EZH2, making it break free from a particular histone known as H3. If it is not bound to H3, EZH2 cannot methylate H3, thus these silenced genes (which are believed to be oncogenes) are re-expressed. If Akt is not activated, it does not phosphorylate EZH2, and this enzyme remains bound to and methylates H3, allowing it to silence gene expression.

"Our results imply that Akt regulates the methylation activity through phosphorylation of EZH2, which may contribute to oncogenesis," Hung says.

Nancy Jensen | EurekAlert!
Further information:
http://www.mdanderson.org

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Researchers invent tiny, light-powered wires to modulate brain's electrical signals

21.02.2018 | Life Sciences

The “Holy Grail” of peptide chemistry: Making peptide active agents available orally

21.02.2018 | Life Sciences

Atomic structure of ultrasound material not what anyone expected

21.02.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>